06619e ONLINE BIOLOGY STRATEGY MEETING 2020 · Strategic Partnership & Outsourcing TRACK 6: Target Validation 2019 ATTENDEES CONTRIBUTORS TO THE AGENDA 06619e ... Strategic networking

GET IN TOUCH WITH US:

Click here to find out whatour clients think about ourSTRATEGY MEETINGS

ONLINE BIOLOGYSTRATEGY MEETING 2020

12th November 2020, Thursday 1:00pm - 6:00pm UK | 8:00am - 1:00pm EST

UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com Connect with us

SPONSORS

AGENDA

KEYNOTE PRESENTATION

TRACK 1: In Silico Biology & Informatics

TRACK 2: DMPK & ADME

TRACK 3: In Vivo & In Vitro Pharmacology

TRACK 4: Structural Biology & Biophysics

TRACK 5: Strategic Partnership & Outsourcing

TRACK 6: Target Validation

2019 ATTENDEES

CONTRIBUTORS TO THE AGENDA

06619e

Jon MooreChief Executive Officer Pheno Therapeutics

Laurent AudolyCEO & FounderParthenon Therapeutics

Guy LewyCSOSublime Therapeutics

Bill Farley Vice PresidentSorrento Therapeutics

Philip BeerPrecision Oncology Expert Sanger Institute

Lassina Badolo Director Discovery NCE Drug DispositionMerck Serono

Marcie GlicksmanHead of BiologyEnClear Therapies

Rob HowesDirector Discovery BiologyAstraZeneca

OUR UNIQUE ONLINE MEETING FORMATRoundtable DiscussionsThese interactive and informal discussion groups are the hallmark of the meeting. The brightest minds in the industry are brought together in 60-minute sessions that enable participants from all over the world to share ideas, challenges and lessons learned.

Personalised AgendaEach delegate receives a personalised agenda with the roundtable discussions that you choose. You only attend sessions and meetings that fit your challenges and interests, ensuring your time spent on the online platform is focused and well-utilised.

Innovative SolutionsWhatever your challenge may be, let our official event partners find the solution. Gain access to our carefully selected solution providers and find your next strategic partner that will help take your business to the next level.

Strategic NetworkingStrategic networking opportunities form a key benefit of the meeting. Our new online format for building and strengthening alliances to make lasting connections that benefit you.

OUR VISION

OUR MISSION

To be a platform for creating life-saving therapies and to facilitate the creation of a completely patient centric pharmaceutical industry.

By encouraging key leaders and their companies to put the patient at the very heart beat of every innovation. Sharing valuable insights and strategies to assist in the discovery, development and commercialisation of life saving therapies.

https://proventainternational.com/testimonials/

mailto:info%40proventainternational.com?subject=

https://proventainternational.com/

https://www.facebook.com/proventainternational

https://twitter.com/proventaintl

https://www.linkedin.com/company/proventa-international/

https://www.youtube.com/channel/UCwbeSVlm92MnddSH05XXcTA

UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com

SPONSORSOUR

02GO TO MENU PREVIOUS PAGE NEXT PAGE

PRO-PARTNERS EXHIBITOR

At PerkinElmer Informatics, our focus is on redefining how labs in Pharma, Biotech, Chemicals and major academic centers embrace electronic data capture, cloud-based applications and collaborative tools to manage and analyze their data. With our cloud based collaboration solutions and powerful visual analytics platforms, critical scientific data transforms into actionable insights in an automated, predictive and scalable way. Our solutions include the industry leading ChemDraw application, robust ELN, advanced analytics powered by TIBCO® Spotfire and the Signals Platform. The cloud based PerkinElmer SignalsTM platform unlocks the hidden knowledge within your scientific data whether you are working independently or collaboratively with solutions for Translational Medicine, Screening, Lead Discovery, and Biologics.

Sai Life Sciences is a full-service CDMO driven by a vision to support the launch of 25 new medicines with our partners by 2025. Sai Life Sciences provides services to our pharma innovator partners, which accelerate the discovery, development and manufacture of complex small molecule therapeutic agents. Our clients gain clear competitive advantages through shorter time to market and risk minimization using our integrated and high-quality scientific services. Established in 1999, Sai has over 2,000 employees located at six R&D and manufacturing sites in India, the UK and USA. As one of India’s fastest growing CDMOs, the company is investing over US $ 150 M in augmenting its R&D and manufacturing capabilities, including setting up a Biology Lab in Cambridge, Mass. (USA) and a Process R&D Lab in Manchester, UK. Sai provides high value integrated services in all areas of chemistry from hit discovery to GMP manufacturing, pharmacology, DMPK, toxicology and formulation development to better support the increasing needs of our customers. Sai Life Sciences is backed by TPG Capital and HBM Healthcare Investments.

CO-HOST SPONSORS




https://enamine.net/

https://www.jubl.com/

https://www.perkinelmer.com/

https://www.sailife.com/

https://www.caymanchem.com/

https://www.pelagobio.com/

https://www.dotmatics.com/

https://www.nfventures.co.uk/

https://www.novalix.com/


AGENDAPART 1

TRACK & ROOM(TIME - UK)

01 - IN SILICO BIOLOGY & INFORMATICS 02 - DMPK & ADME 03 - IN VIVO & IN VITRO

PHARMACOLOGY04 - STRUCTURAL BIOLOGY

& BIOPHYSICS 05 - STRATEGIC PARTNERSHIP

& OUTSOURCING 06 - TARGET VALIDATION

1:00pm - 1:30pm UK KEYNOTE PRESENTATION

1:30pm - 1:45pm UK BREAK

1:45pm - 2:45pm UK

Evolving with the digital era: How the landscape of preclinical biology is changing and will change with innovations in computational biology

Innovations in Technology - Optimising DMPK with AI and in silico Simulations

Outsourcing in vivo and in vitro experiments - comparative analysis of vendors in regards to price, location, capabilities and characteristics Marcie Glicksman — Head of Biology, EnClear Therapies

Biophysics in drug discovery: impact, challenges and opportunities

When? Where? How? - Best Outsourcing Practices and Strategies Bill Farley — Vice President, Sorrento Therapeutics

Strategies to ensure effective target validation to mitigate the lack efficacy in humans for oncological therapeutics Philip Beer — Precision Oncology Expert, Sanger Institute


3:00pm - 4:00pm UK

Improving non-clinical GLP toxicology studies to reduce failed candidates Title TBC

Accurately translating in vitro data to correlate with in vivo animal and human models Title TBC

Investigating energetics and thermodynamics of biomolecular interactions with very high precision Title TBC

Communication is key - effective vendor oversight strategies Title TBC

Effectively utilising in silico simulations and modelling technologiex to increase target validation success and improve efficacy in clinical trials Title TBC


4:15pm - 4:45pm UK KEYNOTE PRESENTATION


5:00pm - 6:00pm UK

Effectively utilising in silico generated data to make better informed decisions and reduce preclinical costs

Beyond the rule of 5 in small molecules drug discovery: How well is DMPK prepared?Lassina Badolo — Director, Discovery DMPK, Merck

Better understanding DDIs for non-CYP enzymes to avoid unnecessary DDI trials

Best biophysical techniques to accelerate and deepen the understanding of ligand interactions with biological target

How to improve current alliances and gain more effective collaborations

Validating targets emerging from genetic & small molecule screens in neuroscience, oncology & virology Jon Moore — CEO, Pheno Therapeutics

END






KEYNOTE PRESENTATION


SpeakerTBC

Topic TBC

1:00pm - 1:30pm UK 4:15pm - 4:45pm UK

1ST KEYNOTE PRESENTATION

SpeakerTBC

Topic TBC

2ND KEYNOTE PRESENTATION





TRACK 1In Silico Biology &

Informatics



SpeakerTBC

SpeakerTBC

Evolving with the digital era: How the landscape of preclinical biology is changing and will change with innovations in computational biology

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

Jubilant Biosys

Using Digital Laboratory Informatics to create compliant and efficient lab workflows - Title TBC

SPONSOR

Effectively utilising in silico generated data to make better informed decisions and reduce preclinical costs




TRACK 2DMPK & ADME



SpeakerTBC

Lassina BadoloDirector, Discovery DMPK

Merck

Innovations in Technology - Optimising DMPK with AI and in silico Simulations

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SpeakerTBC

Improving non-clinical GLP toxicology studies to reduce failed candidates

SPONSOR

Beyond the rule of 5 in small molecules drug discovery: How well is DMPK prepared?




TRACK 3In Vivo & In Vitro

Pharmacology



Marcie GlicksmanHead of Biology

EnClear Therapies

SpeakerTBC

Outsourcing in vivo and in vitro experiments - comparative analysis of vendors in regards to price, location, capabilities and characteristics

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SpeakerTBC

Accurately translating in vitro data to correlate with in vivo animal and human models

SPONSOR

Better understanding DDIs for non-CYP enzymes to avoid unnecessary DDI trials




TRACK 4Structural Biology &

Biophysics



SpeakerTBC

SpeakerTBC

Biophysics in drug discovery: impact, challenges and opportunities

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SpeakerTBC

Investigating energetics and thermodynamics of biomolecular interactions with very high precision

SPONSOR

Best biophysical techniques to accelerate and deepen the understanding of ligand interactions with biological target




TRACK 5Strategic Partnership

& Outsourcing



Bill Farley Vice President

Sorrento Therapeutics

SpeakerTBC

When? Where? How? - Best Outsourcing Practices and Strategies

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SpeakerTBC

Communication is key - effective vendor oversight strategies

SPONSOR

How to improve current alliances and gain more effective collaborations




TRACK 6Target Validation



Philip BeerPrecision Oncology Expert

Sanger Institute

Jon MooreChief Executive Officer

Pheno Therapeutics

Strategies to ensure effective target validation to mitigate the lack efficacy in humans for oncological therapeutics

1:45pm - 2:45pm UK

3:00pm - 4:00pm UK

5:00pm - 6:00pm UK

SpeakerTBC

Effectively utilising in silico simulations and modelling technologiex to increase target validation success and improve efficacy in clinical trials

SPONSOR

Validating targets emerging from genetic & small molecule screens in neuroscience, oncology & virology



UK: +44 (0)207 096 1222US: +44 (0)20 3314 0100 [email protected] www.proventainternational.com 11

2019 ATTENDEES

GO TO MENU PREVIOUS PAGE


COMPANY JOB TITLEA2A Pharmaceuticals Chief Scientific OfficerA2A Pharmaceuticals Director of Business Development and R&D StrategyAbimmune Biotherapeutics Chief Executive OfficerAccent Therapeutics Head of Lead DiscoveryAccent Therapeutics Vice President, Molecular DiscoveryAccent Therapeutics Associate Director, Head of Protein and Structural

SciencesAgios Pharmaceuticals Senior Reseach FellowAgios Pharmaceuticals Associate DirectorAgios Pharmaceuticals Director, Discovery DMPKAgios Pharmaceuticals Principal Scientist/Associate DirectorAkebia Therapeutics Principal Scientist, DMPK LeadAlkermes Head, Target BiologyAlnylam Associate DirectorAMGEN Principal ScientistAngex Pharmaceutical Inc Vice President of BiologyAOBiome Vice President of R&DArkuda Therapeutics Senior Director, BiologyArkuda Therapeutics SVP Pharmacology & Translational SciencesArrakis Therapeutics Associate DirectorAsana BioSciences DirectorAsana BioSciences DirectorAstrazeneca Associate principal scientistAveta Biomics Chief Executive OfficerBiogen Principal Scientist / Biotransformation Group LeadBMS Senior Principal ScientistC4 Therapeutics Director, Biochemistry, Biophysics & CrystallographyC4 Therapeutics Vice President Early DevelopmentCold Genesys Chief Scientific OfficerComet Therapeutics Research DirectorCullinan Oncology Vice President, Preclinical Research and Early

DevelopmentCygnal Tx SVP Small Molecule Drug DiscoveryElstar Therapeutics ScientistElstar Therapeutics Senior ScientistEMD Serono Associate Director

COMPANY JOB TITLEEMD Serono R&D Institute Assoc Scientific DirectorEpizyme Inc Executive DirectorFerring Research Institute, Inc

Associate Director, ADME

Foghorn Therapeutics Director, DMPKForkhead BioTherapeutics Chief Scientific Officer and Co-FounderForkhead BioTherapeutics Vice President of Chemistry Forkhead BioTherapeutics Chief Executive Officer and Co-FounderForma Therapeutics Director, Early DiscoveryFrequency Therapeutics Chief Medical OfficerFrequency Therapeutics Senior Manager – New Frontiers in Regenerative

MedicineFrequency Therapeutics Vice President, Regulatory AffairsFulcrum Therapeutics Director of ToxicologyFulcrum Therapeutics Lead ScientistGlaxoSmithKline Director, Functional GenomicsGlyde Bio, Inc. Founder & CEOGoldfinch Bio Vice President, BiologyGotham Therapeutics Vice President, BiologyHiFiBiO Chief Executive OfficerHotSpot Therapeutics, Inc. Senior Director, Biochemistry & BiophysicsIncyte Director, Antibody Analytics & EngineeringInnovation Pharmaceuticals DirectorIntellia Therapeutics Senior VP, Clinical and Preclinical SciencesJounce Therapeutics Senior DirectorKaryopharm Senior Director, Clinical PharmacologyKintai Therapeutics Vice President, BiologyKSQ Therapeutics Senior Director, Head of PharmacologyKymera Therapeutics Vice President, Translational MedicineKymera Therapeutics Director Translational MedicineLarry Hardy Research DirectorLifeMine Therapeutics Senior DirectorLogicbio Therapeutics Vice President, Biology & Translational Res.Lotze University of PittsburghMerck Director, PharmacologyMomenta Pharmaceuticals Principal Scientist (Program Lead)Morphic Therapeutic Head of Structural BiologyNimbus Therapeutics Senior Vice President, Chemistry

COMPANY JOB TITLE

Novartis Executive Director, PK Sciences - Global Head Opthamology

Novartis Senior Scientist I (lead)Novartis Institute of Biomedical Research

Principal Pharmacometrician

Ovid Rx DirectorPfizer Director, Molecular & Cellular BiologyPfizer Executive Director, Head Primary Pharmacology GroupPfizer Vice President, Preclinical Biology I&I ResearchPromedior Senior Director, AnalyticalProteostasis Therapeutics, Inc.

Senior Director of Biology

PTC Therapeutics Head Gene Therapy Nonclinical ResearchRanok Therapeutics Vice President, BiologyRelay Therapeutics Associate Director DMPKRibon Therapeutics Associate Director, Structural Biology and Protein

SciencesRiparian Pharmaceuticals DirectorSanofi Project LeadSanofi Senior Director & Head, Antibody DiscoverySanofi Senior Director/Group Head Sarepta Therapeutics Scientist I, Modeling and SimulationTakeda Associate DirectorTakeda Associate Director, Lead DiscoveryTakeda DirectorTakeda Executive DirectorTakeda Principal ScientistTakeda Principal scientist/Associate DirectorTakeda Senior Director of PK and TR Group Takeda Oncology Associate DirectorTakeda Pharmaceuticals ScientistTesaro Senior Director, Protein SciencesTESARO/GSK Director CPDDTwentyeight-Seven Therapeutics

Director, Preclinical Biology

Valerion Therapeutics Chief Scientific OfficerX-Chem Vice President of Biology Zafgen Vice President, Discovery Research



06619e ONLINE BIOLOGY STRATEGY MEETING 2020 · Strategic Partnership & Outsourcing TRACK 6: Target Validation 2019 ATTENDEES CONTRIBUTORS TO THE AGENDA 06619e ... Strategic networking

Documents